Seattle Genetics, Inc.  

(Public, NASDAQ:SGEN)   Watch this stock  
Find more results for sgen
-0.75 (-2.08%)
Mar 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.16 - 36.29
52 week 30.05 - 47.67
Open 36.09
Vol / Avg. 675,583.00/1.23M
Mkt cap 4.49B
P/E     -
Div/yield     -
EPS -0.62
Shares 124.32M
Beta 1.42
Inst. own 104%
May 11, 2015
Seattle Genetics Annual Shareholder Meeting (Estimated) Add to calendar
Apr 29, 2015
Q1 2015 Seattle Genetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 11, 2015
Seattle Genetics Inc at Barclays Healthcare Conference
Mar 4, 2015
Seattle Genetics Inc at Cowen Health Care Conference
Feb 12, 2015
Seattle Genetics Inc at Leerink Global Healthcare Conference
Feb 10, 2015
Q4 2014 Seattle Genetics Inc Earnings Call - Webcast
Feb 10, 2015
Q4 2014 Seattle Genetics Inc Earnings Release
Jan 12, 2015
Seattle Genetics Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -35.90% -26.55%
Operating margin -37.30% -26.98%
EBITD margin - -22.62%
Return on average assets -22.84% -16.15%
Return on average equity -49.09% -34.53%
Employees 657 -
CDP Score - -


21823 30th Dr SE
BOTHELL, WA 98021-3907
United States - Map
+1-425-5274000 (Phone)
+1-425-5274001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Seattle Genetics, Inc. is a biotechnology Company focused on developing and commercializing antibody-based therapies for the treatment of cancer. The Company�s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, its pipeline includes six clinical-stage ADC programs consisting of SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and multiple preclinical programs including SEA-CD40, a non-fucosylated anti-CD40 antibody utilizing a immuno-oncology technology. Its technologies include antibody-drug conjugate (ADC) technology and Seattle Genetics sugar-engineered antibody (SEA) technology. The Company�s pipeline of monoclonal antibody-based product candidates is based on its ADC technology.

Officers and directors

Clay B. Siegall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Todd E. Simpson Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Eric L. Dobmeier Chief Operating Officer, Corporate Secretary
Age: 45
Bio & Compensation  - Reuters
Jean I. Liu J.D. Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
Age: 45
Bio & Compensation  - Reuters
Christopher S. Boerner Ph.D. Executive Vice President - Commercial
Age: 43
Bio & Compensation  - Reuters
Jonathan Drachman M.D. Chief Medical Officer and Executive Vice President, Research and Development
Age: 52
Bio & Compensation  - Reuters
Vaughn B. Himes Ph.D. Executive Vice President - Technical Operations, Process Sciences
Age: 53
Bio & Compensation  - Reuters
Charles R. Romp Senior Vice President - Sales
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Lead Independent Director
Age: 45
Bio & Compensation  - Reuters
John A. Orwin Director
Age: 49
Bio & Compensation  - Reuters